A model of Protein C (PC) activation in vivo was used t o investigate the complexing of activated PC (APC) with its plasma inhibitors, PC inhibitor (PCI) and a1 -antitrypsin (arlAT). Chimpanzees were infused with a bolus of activated factor X (F.Xa) together with vesicles of phosphatidylcholine and phosphatidylserine (PCPS). Pre-and postinfusion plasma samples were analyzed using enzyme linked immunosorbent based assays (ELISA) for PC and APC complexes, and immunoblotting of PC from nondenaturing polyacrylamide gel electrophoresis. Within 2 minutes of infusion, a 60% decrease in nonactivated PC zymogen (PC,) levels was observed. This coincided with a precipitous drop in plasma activities of cofactors Villa and Va. In contrast, total PC antigen (PCJ levels decreased by only 1%. indicating APC generation. Complexes of APC with both PCI and a l A T were observed on immunoblots. and further identified and quantified using a sandwich ELISA employing antibodies t o both PC and these inhibitors. The distribution of APC between these two inhibitors varied with the dose of F.Xa/PCPS infused. At a dose of ROTEIN C (PC) is a vitamin K-dependent plasma P protein zymogen, circulating at levels of 3 to 4 Fg/mL in humans.' It can be rapidly activated to form activated PC (APC) by thrombin' or activated factor X3 in the presence of thrombomodulin, an endothelial cell c~f a c t o r .~ APC exhibits anticoagulant activity by proteolytically inactivating activated factors VI11 and V,5,6 and has also been reported to have profibrinolytic activity, possibly by neutralizing plasminogen activator inhibitors.'~~ Two inhibitors of APC have been described to date, both of which are members of the SERPIN family. PC Inhibitor (PCI) is heparin-dependent and was first characterized by Suzuki et aL9 It has been shown to be immunologically identical to plasminogen activator inhibitor-3 (PAI-3).103" In the presence of heparin, PCI inhibits APC, urokinase, t-PA, thrombin, activated factor X, trypsin and chymotrypsin",'* iments with lower doses of F.Xa/PCPS suggest that PCI is the preferred inhibitor of APC, but as the availability of this inhibitor becomes limiting, a1 AT plays an increasingly crucial role as a secondary inhibitor of endogenously generated APC. Moreover, evidence is presented suggesting the existence of additional inhibitor(s) of APC that may have a role similar to a1 AT.
F.Xa/PCPS of 24.05 pmol and 37.70 nmol/kg, respectively, an initial spike of APC generation, associated with decreases in the levels of factors Vllla and Va, was noted but dissipated over the next 30 minutes. During this period, APC/inhibitor complexes appeared with the levels of APC-PCI and APC-dAT reaching 8.5 nmol/L and 2.2 nmol/L by 30 minutes, respectively. In contrast, at a higher dose of F.Xa/PCPS of 36.60 pmol and 56.30 nmol/Kg respectively, complexes of APC-a1 AT appeared rapidly and reached a level of 6 nmol/L by 30 minutes postinfusion, whereas APC-PCI complexes were only present at a concentration of 3.4 nmol/L by this time. Additional experiments with lower doses of F.Xa/PCPS suggest that PCI is the preferred inhibitor of APC, but as the availability of this inhibitor becomes limiting, a1 AT plays an increasingly crucial role as a secondary inhibitor of endogenously generated APC. Moreover, evidence is presented suggesting the existence of additional inhibitor(s) of APC that may have a role similar to a1 AT. 0 1990 by The American Society of Hematology.
activated factor XI, and kallikrein. 13 Recently, a second heparin-independent inhibitor of APC was des~ribed'~~'' and subsequently shown to be immunologically identical to a lantitrypsin (culAT),I6 also called al-proteinase inhibitor.
We have previously described a dog model of PC activation in vivo in which the infusion of a procoagulant combination of activated factor X (F.Xa), plus vesicles of phosphatidylcholine and phosphatidylserine (PCPS) results in the endogenous generation of thrombin and APC.'.'' The appearance of higher molecular weight (mol wt) complexes (97 Kd) of PC antigen was demonstrated on immunoblots from sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of postinfusion plasma samples." Although these appeared to be complexes of APC with the heparinindependent inhibitor, we were unable to characterize these further due to lack of specific antibodies to the canine APC-inhibitors. These studies have now been extended to a primate model (chimpanzee), where available crossreacting antibodies to human proteins could be used to immunologically identify and quantify the inhibitor complexes observed.
MATERIALS AND METHODS

Materials.
Protein A sepharose 4B and CNBr-activated sepharose 4B were purchased from Pharmacia LKB Biotechnology (Uppsala, Sweden). Chromogenic substrates S2238 and S2366 were purchased from KabiVitrum (Stockholm, Proteins. with the modification that dextran sulphate sepharose chromatography, described by Pepper and Prowse?" was substituted for preparative electrophoresis. PC (1.94 mg/mL in Tris-buffered saline [TBS]: 0.02 mol/L Tris-HCI, 0.15 mol/L NaCl pH 7.4) was activated by the addition of purified thrombin to 35 pg/mL final concentration and incubated at 37OC. At timed intervals, 2-pL aliquots were tested for amidolytic activity in a total volume of 0.2 mL of 0.02 mol/L Tris-HCI pH 8.3, 0.15 mol/L NaCI, 1 g% (wt/vol) polyethylene glycol 8000 pH 8.3 containing 10 pg/mL ATIII and 1 U/mL heparin. One hundred microliters of 1 mmol/L S-2366 was then added, and the rate of change of absorbance at 405 nm monitored at 37OC. When maximal activity was reached, the thrombin was removed by passing the mixture over a 5-mL column of SP-sephadex equilibrated in TBS. The unbound protein was pooled and frozen at -70°C. Human factor X was prepared and activated as previously de~cribed.~ Purified human a1 AT was purchased from Calbiochem.
Protein concentrations were determined by absorbance using E" = 14.5 for human PC? 4.36 for human o~A T , '~ and 13.4 for immunoglobulin G (IgG).2 ' Human PC was iodinated to a specific radioactivity of 10 pCi/pg using Iodobeads as per manufacturers instructions. The mixture was then removed from the beads and gel-filtered at 22OC on a 0.7 x 18 cm column of Sephadex G-25 in TBS containing 2 mg/mL BSA. The peak obtained in the excluded volume was pooled and frozen in aliquots at -7OOC.
Polyclonal rabbit antiserums to human a1 AT and to human C1-inhibitor were purchased from Hoechst Canada (Montreal, Quebec). Purified IgG from rabbit antiserum to human 02-macroglobulin was purchased from Dako Corp (Santa Barbara, CA). A monoclonal antibody (MoAb) to PAI-3 (10A6A10) was a generous gift of Dr D. Stump (University of Vermont, Burlington). MoAbs directed to the activation peptide of PC (PC-121) or to an epitope on the light chain of PC (7D7) were kindly donated by Dr Fred Walker (American Red Cross, Farmington, CT). Affinity purified EIA grade horseradish peroxidase (HRP) conjugated goat anti-mouse IgG or goat anti-rabbit IgG was purchased from BioRad Laboratories (Richmond, CA). Polyclonal antibodies to human PC were prepared in sheep using standard procedures.2' The polyclonal antibodies were monospecific as determined by immunoelectrophoresis against normal plasma and barium citrate eluates. IgG was purified from sheep serum using the octanoic acid technique,22 and from rabbit serum using protein A affinity ~hromatography.~' To increase the capture capacity of the coated antibody used in the enzyme linked immunosorbent assays (ELISAs), sheep anti-human PC IgG was affinity purified on a 5-mL column of CNBr-activated sepharose, to which 9 mg purified PC was coupled. One hundred milligrams of IgG in 5 mL TBS was applied to the column equilibrated in TBS, and washed with TBS until the AZ8,, was less than 0.02. The bound IgG was then eluted with 0.1 mol/L glycine-HC1, 0.5 mol/L NaCI, pH 2.5, and fractions collected into one-tenth volume of 1 mol/L Tris-HCI pH 8.0. Fractions containing protein were pooled, adjusted to pH 8.0 with Tris, treated with sodium azide at 0.02% (wt/vol) and stored at 4OC. The optimal concentrations of all antibodies used were determined by titration.
Electrophoresis and immunoblotting. Nondenaturing PAGE was performed as described by Davisz4 using 5% acrylamide in 1.5-mm slabs with a 3% stacking gel. Plasma samples were diluted 1:3 in sample buffer containing 20 mmol/L EDTA and a 4-pL aliquot applied to each well. Electrophoresis was performed initially at 60 V for 30 minutes, and then 150 V to completion. Protein transfer to Immobilon membrane was performed according to the method of Towbin and Gordon" using a Transphor unit (Pharmacia Human PC was purified as described by Bajaj et Iodination.
Antibodies.
LKB Biotechnology) for 2 hours at 4OC at 500 mA in 25 mmol/L Tris, 192 mmol/L glycine, and 20% (vol/vol) methanol, pH 8.3. Immunostaining of PVDF membranes was performed according to the method of Lammle et aIz6 with the following modifications. Membranes were blocked overnight at 4OC in a solution of phosphatebuffered saline (PBS) (0.015 mol/L NaHPO, pH 7.4, 0.14 mol/L NaCI, 0.002 mmol/L KCl) containing 50 mg/mL BSA and PPACK (1 pmol/L), Dans-EGR-CK (1 pmol/L), and Phe-Phe-Arg-CK (1 pmol/L), pH 7.4 (blocking buffer). The blocked membranes were incubated for 3 hours at 22OC with sheep anti-PC IgG (not affinity purified) at 25 pg/mL in PBS containing 50 mg/mL Carnation powdered skim milk (Carnation Inc, Toronto, Ontario, Canada), 0.1% Tween 20 (vol/vol) and 1 pmol/L each of PPACK, Dans-EGR-CK, and Phe-Phe-Arg-CK (probing buffer). Membranes were washed for three IO-minute intervals in PBS with 0.1% Tween-20, and then incubated for 1 hour with 1-125 labeled PC, diluted to 500,000 cpm/mL in probing buffer. After three further 10-minute washes, the blots were exposed to Kodak XAR-5 film (Eastman Kodak Co, Rochester, NY) with Lanex intensifying screens at To measure APC-inhibitor complexes, PVC microtiter plates were coated for 2 hours at 22OC with affinity-purified sheep anti-human PC IgG diluted in 20 mmol/L Na2C03 buffer, pH 9.6 (25 pg/mL, 110 pL/well). The wells were emptied, 150 pL of PBS containing 20 mg/mL BSA applied per well, incubated for 2 hours, and finally washed four times with PBS-Tween (200 pL/well). Samples were diluted at least 50-fold in PBS with 0.1% Tween-20 and 1 pmol/L each of PPACK, Dans-EGR-CK and Phe-Phe-Arg-CK, 100 pL/ well applied and incubated for 16 hours at 4OC. The plates were washed four times with PBS-Tween, and 100 pL of the second antibody diluted in the above-mentioned sample dilution buffer was applied to each well. Complexes of APC with PCI and d A T were detected and quantified using an MoAb to PCI (10A6A10) at 1 pg/mL, or a polyclonal rabbit antibody to a l A T at 10 pg/mL, respectively. After a 2-hour incubation at 22OC, the plates were washed four times with PBS-Tween. Goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP conjugates diluted 1/1,000 in PBSTween were then applied (100 pL/well), and incubation continued at 22OC for 1 hour. Plates were again washed four times with PBS-Tween, then developed with 0.4 mg/mL orthophenylenediamine (OPD) and 0.03% H202 (vol/vol). After 15 minutes the reaction was quenched by the addition of 2.5 mol/L H2S0,, 50 pL/well.
Total PC antigen (PC,) was measured using an MoAb to the light chain of PC (7D7) at 2 pg/mL as a second antibody. PC zymogen (PC,) was measured using an MoAb PC-121 directed to the activation peptide at 2 pg/mL as the second antibody in the PC, measurement. The activation peptide is proteolytically removed from PC on activation2 and therefore is not present in APC and APC-inhibitor complexes. These second antibodies were detected with Goat anti-mouse IgG-HRP conjugates as above. Plasma values were read from a standard line obtained by using a preparation of purified human PC.
A reference standard of APC in complex with a 1 AT was prepared by incubating purified human APC with a 20-fold molar excess of oIAT in TBS and incubated at 37OC until greater than 90% of the APC was inhibited as determined by amidolytic activity as described above. A reference standard of APC-PCI was prepared by the addition of APC to 0.35 pg/mL in PC-depleted plasma in the presence of 10 U/mL heparin, and incubated at 37°C for 30 minutes. PPACK was then added to 25 pmol/L final concentration and aliquots frozen at -7OOC. Analysis of this standard by assays of PC,, PC,, APC-01 AT, and PC immunoblots demonstrated that greater than 90% of the APC added was complexed to PCI.
Quantitative assays of PC and APC complexes.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Activation of plasma PC in vitro was accomplished by the addition of 100 pL Protac (3 U/mL) to 100 pL citrated plasma containing 2 pL of 1,000 U/mL heparin or 2 pL TBS. After 30 minutes' incubation at 37OC, PPACK was added to 25 pmol/L (final concentration).
The experimental protocol used was as follows: normal adult male chimpanzees (pan troglydytes) weighing 50 to 60 kg, were used. These animals are members of a permanent primate colony maintained at the Laboratory for Experimental Medicine and Surgery in Primates of New York Medical Centre (LEMSIP). The animals were anesthetized with ketamine-HCl (10 mg/kg body weight), and atropine-SO, was used as an antisecretory agent. An angiocath was placed in a cubital vein and connected to a three-way stopcock for an isotonic saline infusion and sampling. Mixtures of F.Xa/PCPS were made immediately before infusion in TBS containing 1 g% PEG-8000 (wt/vol). The total volume of F.Xa/PCPS infused was restricted to 20 mL, administered at a constant infusion rate over 30 seconds. The study protocol used had received prior approval by the LEMSIP Institutional Animal Care and Use Committee. Initially a high (36.6 pmo1/56.3 nmol F.Xa/PCPS, respectively per kilogram and a low (24.5 pmo1/37.7 nmol F.Xa/ PCPS per kilogram) dose of the procoagulant mixture were studied. Subsequently, the effects of lower doses of 17 pmol plus 26.2 nmol, and 12.25 pmol plus 18.8 nmol F.Xa/PCPS per kilogram were used. One animal was studied at each dose level. Blood samples for activity-based assays were anticoagulated with one-tenth volume of buffered citrate (0.06 mol/L sodium citrate. 0.04 mol/L citric acid). Factors VI11 and V were assayed by one-stage clotting assays as previously described.' For immunoblotting and ELISA studies, whole blood was collected into vacutainer tubes containing lyophilized EDTA, PPACK, and trasylol (kindly provided by Dr D. Stump, University of Vermont) to give final concentrations of 4.5 mmol/L, 20 pmol/L, and 150 KIU/mL, respectively. Samples were obtained immediately before F.Xa/PCPS infusion and then at 2, 5, 10, 15,20, 30,45,60, and 90 minutes postinfusion.
Animal studies.
RESULTS
The bolus infusion of F.Xa/PCPS a t doses of 24.50 pmol/kg F.Xa, plus 37.70 nmol/kg PCPS (low dose), or 36.60 pmol/kg F.Xa plus 56.30 nmol/kg PCPS (high dose) into chimpanzees resulted in the endogenous activation of PC. Electrophoretic analysis of PC activation and inactivation. To determine the distribution of P C antigen after the infusion of F.Xa/PCPS, samples were analyzed by immunoblotting using nondenaturing PAGE. The results are shown in Fig 3, A (low dose) and B (high dose). The bands labeled PC and P C are both presumed to be PC as both species were present in all preinfusion plasma samples studied. The P C (Fig 3B) , the 2-and 5-minute postinfusion samples (lanes 2 and 3, respectively) show a band of slightly lower mobility than the nonactivated zymogen PC seen in lane 1. This band is also noted in the first postinfusion sample from the low-dose study (Fig 3A, lane 2) and the preinfusion samples to which Protac had been added in the absence of heparin (Fig 3, A and B, lane 11) . This band is presumed to be APC, since the time a t which it reaches its greatest intensity coincides with the loss of activities of factors VI11 and V, and this appears to decrease and subsequently disappear as the levels of APC-inhibitor complex increase.
Immediately after the infusion of F.Xa/PCPS a t both doses, as many as four additional bands with lower mobility compared with those described above were observed. The most rapidly migrating of these species (band D), most clearly seen in the high dose experiment (Fig 3B) , comigrates with the band that appears after the addition of Protac to the preinfusion specimen in the absence of heparin (Fig 3, A 
TIME ( m i n )
highdose experiment ( fig 3B) . but this change is lest impressive in the low-dose study. In contrast. the band with intermediate mobility (band C) increases in density Over time in both studies and matcha the band that shows a major increase in density in the preinfusion sample to which both Protac and heparin had k e n added. suggesting that this is a complex of APC with the heparindependent inhibitor. PCI. Of interest was the appearance of two very low mobility species of complex in all the postinfusion samples (bands A and R). They were most evident in the highdose study.
where the density of the lowest mobility species (band A) increased aver time. and by 90 minute postinfusion represented the most pmmlent species of complex. were generated. but at the highat dose, this correlation was last and only modest levels were attained. In contrast. the levels of APC-crl AT (Fig 5) showed a d i m relationship to the daxe of F.Xa/PCPS used throughout the whole time course of study.
To ual levels, when assessed by thrombogenicity in a rabbit Therefore, the magnitude of their effect is linear in either one, when the other is held at a fixed level. Thus, the plot shown in Fig 6, in effect, represents an approximation of the dose response for either component in the presence of a fixed concentration of the other. Although the impact of these data should be qualified by emphasizing that each data point represents a single experiment, they nonetheless suggest that the loss of PC zymogen, ie, the extent of PC activation, increased with the dose of F.Xa/PCPS. At relatively modest doses of F.Xa/PCPS, PCI was the preferred inhibitor of APC. As the dose increased, APC-PCI approached a maximum and an increasing fraction of the APC generated was found in complex with a l A T . Thus, the distribution of APC between these two inhibitors appeared to be dependent on the extent of activation of PC and perhaps other zymogens, with PCI being the preferred inhibitor of APC, and a l A T subsequently assuming a major inhibitory role as PCI is consumed. PC zymogen (PC,) was expressed as the percentage that determined in the preinfusion sample in each study.
The concentration of free (uncomplexed) APC was derived by subtracting the sum of the concentratons of PC, and complexes of APC with PCI and a I A T from that of the PC, determined for each sample, according to the formula: Figure 7 shows plots of the derived free APC levels determined at each time point compared with the sum of the measured levels of APC in complex with PCI and cvl A T over time for the low- (Fig 7A) and high-dose (Fig 7B) experiments. In each case, an initial burst of free APC is calculated within the first 2 minutes, indicating extensive activation of PC. This coincides with the appearance of a band on PAGE migrating with the mobility of purified APC (Fig 3) and the substantial loss of activity of factors Va and VIIIa (Fig 2) . In the low-dose study the derived levels of APC peaked at 2 minutes and declined to baseline values by 30 minute postinfusion. Concurrent with this loss of activity was the appearance of APC in complex with PCI and a1 AT, plateauing at 30 minutes and declining slightly thereafter. A similar pattern was observed for the high dose of F.Xa/PCPS. However, the peak of APC observed at 2 minutes was 34% higher than that observed with the low dose. Moreover, at 60 minute postinfusion the calculated value suggested that free APC was still present. This observation is a t variance with the immunoblotting studies (Fig 3, panel B) where uncomplexed APC is no longer detectable in the sample obtained 60 minutes postinfusion. Given that the value for APC is a derived value, these observations could be accounted for by assuming that a fraction (-25%) of the APC generated a t this dose is complexed to another inhibitor and thus unaccounted for in the formula used. The immunoblots support this proposal, as a complex of very low mobility appears immediately, increases in intensity over the period of observation, and is particularly evident in the high-dose study ( Fig  3B, band A) . In vitro studies. Experiments were undertaken in vitro in an attempt to simulate the in vivo observations. PC in the preinfusion plasma sample was activated in situ with Protac for 30 minutes in the absence or presence of heparin, and levels of PC,, PC,, APC-PCI, and APC-a1AT were measured. From these values, levels of APC were derived. The extent of PC activation in vitro was greater than that achieved in vivo (low dose). This was calculated to be 35.5 Using the low dose in vivo, virtually all of the APC generated was inhibited, as indicated by the relative absence of APC, and its quantitative recovery as complexes with PCI and a 1 AT. Of the APC generated, 77% was inhibited by PCI and 20% by a l A T . In vitro, and in the absence of heparin, 82% of the PC activated was present as uncomplexed APC, with 10% and 9% in complex with PC1 and a l A T , respectively. However, in the presence of heparin, uncomplexed APC comprised only 10% of the total, with 84% and 2.5% being found in complex with PC1 and a l A T , respectively. Thus, under these in vitro conditions, substantial inhibition of APC occurs only in the presence of heparin, and PCI appears to be the predomiant inhibitor. In contrast, a l A T , in either the absence or presence of heparin, is a relatively poor inhibitor. In the low-dose in vivo study, the distribution of APC and APC complexes closely resembles that observed in vitro in the presence of heparin. These data suggest, but do not prove, that a heparin-like cofactor activity may be involved in the formation of the APC-PCI complexes in vivo. Similarly, the formation of APC-a1 AT complexes also appears to be facilitated in vivo.
The data obtained from the high-dose study are somewhat more difficult to interpret due to the presence of additional, unidentified complexes of APC that have not been accounted for in the calculations used to derive the free APC values. However, it is notable that whereas equivalent proportions of APC were found in complex with a I A T with both doses 30 minutes postinfusion, only 13% APC was in complex with PC1 a t this time point in the high-dose study compared with 77% in the low-dose study. This could represent accelerated consumption and/or clearance of PCl after complexing with 
DISCUSSION
The studies described were undertaken to gain qualitative and quantitative information regarding the activation and inactivation of PC in vivo and its distribution between its known inhibitors, specifically PCI and a 1 AT. Quantitative ELISA-based assays were developed to specifically measure PC,, PC,, APC-PCI, and APC-alAT. Evidence is presented that infusion of F.Xa/PCPS in appropriate doses results in the activation of PC in vivo, with simultaneous inactivation of cofactors VIIIa and Va, and the generation of APCinhibitor complexes. Presumably these phenomena are consequent to the endogenous generation of thrombin, and subsequent PC activation in vivo. Since PC activation and subsequent inactivation occurs in vivo in this model, it is likely to reflect the full interplay of those mechanisms normally responsible for the regulation of its activity.
Espana et a128 found that APC perfused into baboons complexed with both PCI and a l A T . The distribution of APC toward a l A T was favored by a relatively high dose of APC, and it was suggested that this occurred as a result of consumption of PCI. Our results are qualitatively similar in that at the lower dose of F.Xa/PCPS, the APC-inhibitor profile, was dominated by PCI, whereas at the higher procoagulant dose, which resulted in a greater degree of PC activation, was dominated by aIAT. However, the levels of APC-PCI plateaued at only 8.0 nmol/L (low dose) and 3.5 nmol/L (high dose). This contrasts with a level of 23 nmol/L formed in vitro when preinfusion plasma was activated with Protac. The latter value corresponds to the level of PCI in chimpanzee plasma (results not shown). The measurement of only 3.5 to 8.5 nmol/L APC-PCI in vivo may reflect rapid clearance or complexing of PCI with other enzymes generated by the infusion of F.Xa/PCPS. These would not have been detected by the assays used. Rapid clearance is not likely since APC-PC1 levels reached a stable plateau. The infusion of F.Xa/PCPS a t relatively high doses is known to induce a substantial coagulant' and fibrinolytic re~ponse.'~ As PC1 (PAI-3) is an inhibitor of many enzymes, including tissue plasminogen activator (t-PA), and given that we have demonstrated a profound increase in the circulating levels of t-PA after the infusion of F.XA/PCPS a t the dosages used in this study,29 it is possible that t-PA and/or other enzymes generated competed with APC for this inhibitor.
Our calculations of free APC suggest that the anticoagulant enzyme can appear transiently in plasma at levels up to 25 nmol/L in response to the procoagulant stimuli studied. The inferred existence of free APC is supported by evidence of its functional, uninhibited activity in the inactivation of cofactors VIIIa and Va, and the appearance of free APC on immunoblots during the same time frame. However, the accuracy of the calculated values is dependent on the validity of the assumption that total PC antigen is distributed exclusively between the zymogen, APC, and complexes of APC with its two known inhibitors, PCI and a l A T . Should APC be present in complex with other proteins, the calculated free APC levels would represent an overestimate. The immunoblotting studies demonstrated other species of APC complex that appear to correlate directly with the amount of APC generated. Their precise identity remains to be determined. Substitution of antibodies directed at a2-macroglobulin, C1-inhibitor, and PAI-1 in the ELISA described did not demonstrate complexi.ng of APC with these inhibitors despite known reactivity of these antibodies with chimpanzee proteins (results not shown). Further study is essential as the data presented suggest that inhibitors yet to be identified may contribute substantially to the inhibition of APC in certain situations in primates, and perhaps also in humans.
